Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: A prospective study of 100 episodes

Medical Science Monitor

Volumn 10, Issue 11, 2004, Pages

  Chamorey, Emmanuel ^a   Magné, Nicolas ^b   Foa, Cyril ^a   Otto, Josiane ^a   Largillier, Rémy ^a   Viot, Michèle ^a   Benard Thiery, Isabelle ^a   Thyss, Antoine ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Ceftriaxone; Low risk febrile neufropenia; Monotherapy; Oncology; Solid tumor

Indexed keywords

CEFTRIAXONE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; PRURITUS; PYREXIA IDIOPATHICA; RASH; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; SOLID TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CEFTRIAXONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFECTION; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 9144252140     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kibbler CC: Neutropenic infections: strategies for empirical therapy. J Antimicrob Chemother, 1995; 36: 107-17
2. Klastersky J: Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer, 1993; 29: S6-S10
3. The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med, 1987; 317: 1692-984
4. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis, 1999; 29: 495-502
5. Pizzo PA, Hathorn JW, Hiemenz J et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med, 1986; 315: 552-58
6. Klastersky J, Paesmans M, Rubenstein EB et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 2000; 18: 3038-51
7. Castagnola E, Paola D, Giacchino R et al: Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer, 1998; 6: 524-28
8. Perry TR, Schentag JJ: Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet, 2001; 40: 685-94
9. Hughes WT, Pizzo PA, Wade JC et al: Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992; 15: 206-15
10. Aparicio J, Oltra A, Llorca C et al: Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer, 1996; 32: 1739-43
11. Biron P, Fuhrmann C, Cure H et al: Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother, 1998; 42: 511-18
12. Del Favero A, Menichetti F, Martino P et al: A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis, 2001; 33: 1295-301
13. Feld R, DePauw B, Berman S et al: Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol, 2000; 18: 3690-98
14. Cornely OA, Salzberger B, Bethe U et al: Ceftriaxone and cefotaxime are equally effective in the treatment of neutropenic fever. Antibiot Chemother, 2000; 50: 37-46
15. Karthaus M, Egerer G, Kullmann KH et al: Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis, 1998; 17: 501-4
16. Karthaus M, Sudhoff T, Fenchel K et al: Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriax-one administration. Wien Med Wochenschr, 1998; 148: 481-87
17. Karthaus M, Wolf HH, Kampfe D et al: Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy, 1998; 44: 343-54
18. Cometta A, Calandra T, Gaya H et al: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano delle Malattie Ematologiche Maligne del Adulto Infection Program. Antimicrob Agents Chemother, 1996; 40: 1108-15
19. Rolston KV, Berkey P, Bodey GP et al: A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med, 1992; 152: 283-91
20. Furno P, Dionisi MS, Bucaneve G et al: Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis. Support Care Cancer, 2000; 8: 293-301
21. Rolston KV: New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis, 1999; 29: 515-21
22. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol, 1992; 10: 316-22
23. Rubenstein EB, Rolston K, Benjamin RS et al: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer, 1993; 71: 3640-46